These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 32523658)

  • 1. The role of romiplostim for pediatric patients with immune thrombocytopenia.
    Al-Samkari H; Grace RF; Kuter DJ
    Ther Adv Hematol; 2020; 11():2040620720912992. PubMed ID: 32523658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia.
    Al-Samkari H; Kuter DJ
    Ther Adv Hematol; 2019; 10():2040620719841735. PubMed ID: 31007886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study.
    Al-Samkari H; Jiang D; Gernsheimer T; Liebman H; Lee S; Wojdyla M; Vredenburg M; Cuker A
    Br J Haematol; 2022 May; 197(3):359-366. PubMed ID: 35179784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists.
    Gilreath J; Lo M; Bubalo J
    Drugs; 2021 Jul; 81(11):1285-1305. PubMed ID: 34160821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Romiplostim for the Treatment of Immune Thrombocytopenia: Spotlight on Patient Acceptability and Ease of Use.
    Gilbert MM; Grimes AB; Kim TO; Despotovic JM
    Patient Prefer Adherence; 2020; 14():1237-1250. PubMed ID: 32801654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
    Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
    Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice.
    Neunert CE; Rose MJ
    Blood Adv; 2019 Jun; 3(12):1907-1915. PubMed ID: 31239245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombopoietin receptor agonist for treatment of immune thrombocytopenia in pregnancy: a narrative review.
    Agarwal N; Mangla A
    Ther Adv Hematol; 2021; 12():20406207211001139. PubMed ID: 33796239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Romiplostim in chronic immune thrombocytopenic purpura.
    Cersosimo RJ
    Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombopoietin receptor agonists and rituximab for treatment of pediatric immune thrombocytopenia: A systematic review and meta-analysis of prospective clinical trials.
    Ayad N; Grace RF; Al-Samkari H
    Pediatr Blood Cancer; 2022 Mar; 69(3):e29447. PubMed ID: 34962697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era.
    Lassandro G; Palladino V; Vecchio GCD; Palmieri VV; Corallo PC; Faienza MF; Giordano P
    Endocr Metab Immune Disord Drug Targets; 2021; 21(3):397-406. PubMed ID: 32473624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of romiplostim in splenectomized and nonsplenectomized patients with immune thrombocytopenia.
    Perdomo J
    Immunotargets Ther; 2016; 5():1-7. PubMed ID: 27529057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia.
    González-Porras JR; Godeau B; Carpenedo M
    Ther Adv Hematol; 2019; 10():2040620719837906. PubMed ID: 31156798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diagnostic approach and treatment of immune thrombocytopenia in adults].
    Kolonić SO; Patekar MB; Milunović V
    Acta Med Croatica; 2013 Mar; 67(1):3-11. PubMed ID: 24279250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia.
    Al-Samkari H; Kuter DJ
    Am J Hematol; 2018 Dec; 93(12):1501-1508. PubMed ID: 30187942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment patterns of thrombopoietin receptor agonists among adults with primary immune thrombocytopenia: A Korean nationwide population-based study.
    Lee JY; Lee JH; Kim SA; Suh KJ; Kim JW; Kim SH; Lee JO; Kim JW; Kim YJ; Lee KW; Kim JH; Lee JS; Bang SM
    Thromb Res; 2022 May; 213():114-118. PubMed ID: 35334441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Review of Romiplostim Mechanism of Action and Clinical Applicability.
    Bussel JB; Soff G; Balduzzi A; Cooper N; Lawrence T; Semple JW
    Drug Des Devel Ther; 2021; 15():2243-2268. PubMed ID: 34079225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Utilization and Efficacy of Thrombopoietin Receptor Agonists in Relapsed/Refractory Immune Thrombocytopenia.
    Arnall JR; DiSogra KY; Downing L; Elmes JB; Tran T; Moore DC
    Am J Ther; 2021 Jan; 28(5):e525-e530. PubMed ID: 33491968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Romiplostim in children with newly diagnosed or persistent primary immune thrombocytopenia.
    Grainger JD; Kühne T; Hippenmeyer J; Cooper N
    Ann Hematol; 2021 Sep; 100(9):2143-2154. PubMed ID: 34308495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults.
    Červinek L; Mayer J; Doubek M
    Int J Hematol; 2015 Jul; 102(1):7-11. PubMed ID: 25833724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.